<p>Prelude Therapeutics（纳斯达克代码：PRLD - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$0.26），超出市场共识预期的（$0.41）$0.15，Zacks 报道。</p>
<p>获取 <strong>Prelude Therapeutics</strong> 的提醒：</p>
<h2>Prelude Therapeutics 股票上涨 2.6%</h2>
<ul>
<li>分析师正在升级这三只股票……原因如下</li>
</ul>
<p>纳斯达克：PRLD 周三上涨 $0.04，达到 $1.39。该公司的股票交易量为 231,680 股，而其平均交易量为 511,617 股。该公司的市值为 7839 万美元，市盈率为 -0.85，贝塔系数为 1.37。该股票的 50 日移动平均价格为 $1.39，200 日移动平均价格为 $1.08。Prelude Therapeutics 的 12 个月低点为 $0.61，12 个月高点为 $4.22。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Prelude Therapeutics 的股份增加了 170.7%。AQR Capital Management LLC 现在拥有 33,823 股该公司的股票，价值 $26,000，此前在上个季度购买了额外的 21,330 股。Marshall Wace LLP 在第二季度购买了 Prelude Therapeutics 的新股份，价值约 $34,000。XTX Topco Ltd 在第二季度将其在 Prelude Therapeutics 的持仓增加了 72.4%。XTX Topco Ltd 现在拥有 42,573 股该公司的股票，价值 $34,000，此前在上个季度购买了额外的 17,873 股。Shay Capital LLC 在第二季度购买了 Prelude Therapeutics 的新持仓，价值约 $61,000。最后，Jane Street Group LLC 在第二季度获得了 Prelude Therapeutics 的新持仓，价值 $74,000。对冲基金和其他机构投资者持有该公司 79.72% 的股份。</p>
<h2>分析师升级和降级</h2>
<p>PRLD 最近受到了一些分析师报告的关注。HC Wainwright 在 9 月 23 日的报告中重申了对 Prelude Therapeutics 的 “买入” 评级，并设定了 $5.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Prelude Therapeutics 的 “卖出（d-）” 评级。Wall Street Zen 在 10 月 18 日的研究报告中将 Prelude Therapeutics 的评级提升至 “持有”。最后，JMP Securities 在 8 月 18 日的研究报告中将 Prelude Therapeutics 的目标价从 $4.00 下调至 $3.00，并对该公司设定了 “市场表现优于大盘” 的评级。两位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 $4.00。</p>
<p><strong>获取我们关于 PRLD 的最新研究报告</strong></p>
<h2>Prelude Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Prelude Therapeutics Incorporated 是一家临床阶段的生物制药公司，专注于为服务不足的患者发现和开发新型精准癌症药物。它正在开发 PRT1419，一种髓系细胞白血病-1 抑制剂，目前正在进行针对选定复发/难治性髓系或 B 细胞恶性肿瘤的 1 期临床试验；PRT2527，一种细胞周期依赖性激酶，目前正在进行针对晚期实体肿瘤的 1 期临床试验；PRT3645，一种细胞周期依赖性激酶 4/6 抑制剂，目前正在进行针对晚期和转移性实体肿瘤的 1 期临床试验；以及 PRT3879，一种 SMARCA2 选择性蛋白降解剂，目前正在进行针对因截断突变和/或缺失导致 SMARCA4 丧失的晚期和转移性实体肿瘤的 2/3 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Prelude Therapeutics 更好</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Rocket Lab 股票在财报后上涨，尽管 Neutron 延迟</li>
<li>3 只最佳金融科技股票以提升投资组合</li>
<li>Occidental Petroleum 在 2025 年第四季度是一个买入机会</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>3 只被打压的股票在本财报季有反弹潜力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJMRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Prelude Therapeutics 吗？</h2>
<p>在你考虑 Prelude Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Prelude Therapeutics 并不在名单上。</p>
<p>虽然 Prelude Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRLD

<p>Prelude Therapeutics 报告的季度每股收益为（$0.26），超出市场共识预期的（$0.41）。股价上涨 2.6%，至$1.39。分析师的评级不一，市场共识为 “持有”，目标价为$4.00。机构投资者持有该股票的 79.72%。该公司正在开发几种癌症治疗方案，目前处于临床试验阶段</p>

<p>Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15, Zacks reports.</p>
<div class="lb-trans"><p>Prelude Therapeutics（纳斯达克代码：PRLD - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$0.26），超出市场共识预期的（$0.41）$0.15，Zacks 报道。</p>
</div><p>Get <strong>Prelude Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prelude Therapeutics</strong> 的提醒：</p>
</div><h2>Prelude Therapeutics Stock Up 2.6%</h2>
<div class="lb-trans"><h2>Prelude Therapeutics 股票上涨 2.6%</h2>
</div><ul>
<li>Analysts are Upgrading These 3 Stocks…Here’s Why</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师正在升级这三只股票……原因如下</li>
</ul>
</div><p>NASDAQ:PRLD traded up $0.04 on Wednesday, reaching $1.39. The company's stock had a trading volume of 231,680 shares, compared to its average volume of 511,617. The firm has a market cap of $78.39 million, a price-to-earnings ratio of -0.85 and a beta of 1.37. The stock has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.08. Prelude Therapeutics has a 12-month low of $0.61 and a 12-month high of $4.22.</p>
<div class="lb-trans"><p>纳斯达克：PRLD 周三上涨 $0.04，达到 $1.39。该公司的股票交易量为 231,680 股，而其平均交易量为 511,617 股。该公司的市值为 7839 万美元，市盈率为 -0.85，贝塔系数为 1.37。该股票的 50 日移动平均价格为 $1.39，200 日移动平均价格为 $1.08。Prelude Therapeutics 的 12 个月低点为 $0.61，12 个月高点为 $4.22。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in Prelude Therapeutics by 170.7% during the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company's stock valued at $26,000 after purchasing an additional 21,330 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Prelude Therapeutics during the second quarter valued at approximately $34,000. XTX Topco Ltd grew its position in Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company's stock valued at $34,000 after buying an additional 17,873 shares in the last quarter. Shay Capital LLC bought a new position in Prelude Therapeutics during the second quarter valued at about $61,000. Finally, Jane Street Group LLC acquired a new position in shares of Prelude Therapeutics in the 2nd quarter worth $74,000. Hedge funds and other institutional investors own 79.72% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Prelude Therapeutics 的股份增加了 170.7%。AQR Capital Management LLC 现在拥有 33,823 股该公司的股票，价值 $26,000，此前在上个季度购买了额外的 21,330 股。Marshall Wace LLP 在第二季度购买了 Prelude Therapeutics 的新股份，价值约 $34,000。XTX Topco Ltd 在第二季度将其在 Prelude Therapeutics 的持仓增加了 72.4%。XTX Topco Ltd 现在拥有 42,573 股该公司的股票，价值 $34,000，此前在上个季度购买了额外的 17,873 股。Shay Capital LLC 在第二季度购买了 Prelude Therapeutics 的新持仓，价值约 $61,000。最后，Jane Street Group LLC 在第二季度获得了 Prelude Therapeutics 的新持仓，价值 $74,000。对冲基金和其他机构投资者持有该公司 79.72% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>PRLD has been the subject of a number of recent analyst reports. HC Wainwright reiterated a &#34;buy&#34; rating and set a $5.00 price target on shares of Prelude Therapeutics in a report on Tuesday, September 23rd. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Prelude Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Prelude Therapeutics to a &#34;hold&#34; rating in a research note on Saturday, October 18th. Finally, JMP Securities reduced their target price on Prelude Therapeutics from $4.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research note on Monday, August 18th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $4.00.</p>
<div class="lb-trans"><p>PRLD 最近受到了一些分析师报告的关注。HC Wainwright 在 9 月 23 日的报告中重申了对 Prelude Therapeutics 的 “买入” 评级，并设定了 $5.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Prelude Therapeutics 的 “卖出（d-）” 评级。Wall Street Zen 在 10 月 18 日的研究报告中将 Prelude Therapeutics 的评级提升至 “持有”。最后，JMP Securities 在 8 月 18 日的研究报告中将 Prelude Therapeutics 的目标价从 $4.00 下调至 $3.00，并对该公司设定了 “市场表现优于大盘” 的评级。两位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 $4.00。</p>
</div><p><strong>Get Our Latest Research Report on PRLD</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 PRLD 的最新研究报告</strong></p>
</div><h2>Prelude Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Prelude Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.</p>
<div class="lb-trans"><p>Prelude Therapeutics Incorporated 是一家临床阶段的生物制药公司，专注于为服务不足的患者发现和开发新型精准癌症药物。它正在开发 PRT1419，一种髓系细胞白血病-1 抑制剂，目前正在进行针对选定复发/难治性髓系或 B 细胞恶性肿瘤的 1 期临床试验；PRT2527，一种细胞周期依赖性激酶，目前正在进行针对晚期实体肿瘤的 1 期临床试验；PRT3645，一种细胞周期依赖性激酶 4/6 抑制剂，目前正在进行针对晚期和转移性实体肿瘤的 1 期临床试验；以及 PRT3879，一种 SMARCA2 选择性蛋白降解剂，目前正在进行针对因截断突变和/或缺失导致 SMARCA4 丧失的晚期和转移性实体肿瘤的 2/3 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Prelude Therapeutics</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Occidental Petroleum is a Buy in Q4 2025</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Prelude Therapeutics 更好</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Rocket Lab 股票在财报后上涨，尽管 Neutron 延迟</li>
<li>3 只最佳金融科技股票以提升投资组合</li>
<li>Occidental Petroleum 在 2025 年第四季度是一个买入机会</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>3 只被打压的股票在本财报季有反弹潜力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJMRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PRLD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prelude Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Prelude Therapeutics 吗？</h2>
</div><p>Before you consider Prelude Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Prelude Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Prelude Therapeutics 并不在名单上。</p>
</div><p>While Prelude Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prelude Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prelude Therapeutics（纳斯达克股票代码：PRLD）公布财报结果